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Patterns of disclosure of Huntington disease risk and genetic
test results among family members are important, but have
been underexplored. We interviewed 21 individuals in-
depth—eight mutation-positive for HD, four mutation-
negative, and nine not tested—for 2 hr each. Within families,
critical questions arose of what, when, and to whom to
disclose, and what to do post-disclosure. Interviewees
wrestled with dilemmas of what to tell (e.g., suspicions vs.
confirmed symptoms; initiation vs. completion of testing;
partial vs. indirect information), how to disclose (e.g.,
planning in advance vs. ‘‘blurting out’’ information in
arguments), and whether and how to tell extended family
members. Questions arose of when to tell (i.e., to avoid
disclosing ‘‘too early’’ or ‘‘too late’’). Similarities and differ-
ences emerged related to types of relationships (e.g., parents
telling offspring vs. offspring telling parents vs. siblings
telling each other). Individuals often disclosed because of
perceived duty to foster the health of their family members,
enabling these others to pursue appropriate medical evalua-
tion, if desired. Yet tensions arose because the information
could burden these members, who also have rights to remain
‘‘in denial’’ if they wish and not discuss the topic or pursue
testing. Post-disclosure, dilemmas emerged of whether and
how much to encourage family members to pursue testing.
These data shed important light on critical issues that have
received little, if any, attention concerning what, how, and
when disclosure occurs, and have key implications for at-risk
individuals, genetic counselors, and other health care work-
ers (HCWs), and for future research. At-risk individuals
would benefit from considering these issues in advance.
HCWs need to realize that these decisions are multi-faceted.
Future research can explore whether, when, how, and how
often HCWs raise these issues with individuals.
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Key words: Huntington disease; genetics; disclosure;
families; secrets; privacy/confidentiality; stigma; ethics;
decision-making; genetic discrimination; children; kinship
How to cite this article: Klitzman R, Thorne D, Williamson J, Chung W, Marder K. 2007.
Disclosures of Huntington disease risk within families: Patterns of decision-making
and implications. Am J Med Genet Part A 143A:1835–1849.
INTRODUCTION
Patterns of disclosures of Huntington disease (HD)
risk and test results among family members are
important, but remain underexplored. HD testing,
once disclosed, can affect families in many ways
[Sobel and Cowan, 2000], but how do individuals
make decisions concerning disclosure of this infor-
mation? In general, individuals do not always
communicate genetic risks to all family members
[Sorenson et al., 2003]. Yet only a few studies have
begun to probe these areas with regard to HD.
Research on disclosures of HD and other genetic
disorders has also tended to focus on whether and
why, but notwhat, how, andwhen disclosure occurs.
Forrest et al. [2003] found that in Northeast
Scotland, disclosures of risk for hereditary breast
and ovarian cancer (HBOC) and/or HD created
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problems for mutation-positive individuals. In these
decisions, pre-existing cultural and familial factors
were important—particularly, relationships in famili-
es, and ‘‘hierarchies and authority structures seen in
the ‘British’ kinship system’’ (which emphasizes
‘‘vertical’’ rather than ‘‘horizontal’’ relations) [Forrest
et al., 2003]. Disclosure was seen as a process rather
than an ‘‘act;’’ and two styles were described,
of ‘‘pragmatism’’ and ‘‘prevarication’’—disclosing
proactively versus looking for ‘‘the right moment.’’
Yet differences may exist in a U.S. setting. In a
second, qualitative study, Hamilton et al. [2005]
interviewed 29 individuals—10 who tested for HD,
2 untested at-risk, and 17 tested or at-risk for HBOC,
and described three processes involved in disclosure
decisions. Participants considered family members’
vulnerability versus receptivity; selected what and to
whom to disclose different aspects of information;
and based timing on the readiness of both the teller
and receiver of the information.Most participants did
not disclose more than the fact of the HD test result
itself, unless asked.
Yet research on other genetic diseases has demon-
strated that disclosure is very complex, and that
numerous barriers exist [Green et al., 1997; Forrest
Keenan et al., 2005]. In general, families are com-
plicated interactive social units, varying in norms
[Sorenson and Wertz, 1986; Sorenson et al., 2003].
Most individuals prefer to have disclosures of genetic
information to family members done by themselves
rather than by health care workers (HCWs) [Lerman
et al., 1998]. Yet genetic information is selectively
communicated [Sorenson et al., 2003]. Though
individuals may disclose to family members the
presence of treatable hereditary nonpolyposis colon
cancer (HNPCC) [Peterson et al., 2003], a significant
portion of patients with balanced chromosomal
abnormalities do not inform all their at-risk relatives
[Suslak et al., 1985; Ayme et al., 1993]. Numerous
obstacles impede communication about breast
cancer [Julian-Reynier et al., 2000], and cystic fibrosis
testing [Fanos and Johnson, 1995]. Overall, whether
disclosure occurs may be associated less with
disease-related factors than with individual, familial,
and socio-cultural factors [Wilson et al., 2004]. With
breast cancer, disclosure may increase with age,
having had cancer [Julian-Reynier et al., 2000], being
amother, havinghigher distress [Tercyak et al., 2001],
older children, and more open parent-adolescent
communication [Tercyak et al., 2002], being a carrier
[Lerman et al., 1998; Hughes et al., 2002], and seeking
support and medical advice [Lerman et al., 1998;
Hughes et al., 2002]. Particular obstacles may hamper
disclosure of genetic HNPCC risks to extended family
members [Peterson, 2005]. With cystic fibrosis,
patients often do not want HCWs to contact relatives
with information [Sorenson et al., 1996], and relatives
are often not interested in free education or
counseling about this disease [Sorenson et al.,
1997]. But HD differs from these other genetic
disorders in critical ways. Plantinga et al. [2003]
explored disclosure among individuals with four
genetic versus four non-genetic conditions, but did
not include HD. These two groups generally did
not differ—for example, both groups objected to a
doctor disclosing information without their knowl-
edge to other family members [Plantinga et al., 2003].
Yet the conditions explored were heterogeneous—
for example, HIV was examined as a non-genetic
disease, though it evokes strong privacy concerns
that may make it similar to certain genetic more than
non-genetic diseases.
In contrast, research on disclosures of HIV has
found that individuals vary in what, how, and when
theydisclose (e.g., disclosing indirectly or in ‘‘code’’).
Disclosures of this other stigmatized disease can be
fraught with guilt [Klitzman, 1997; Klitzman and
Bayer, 2003].
But most research on genetic disclosure has
examined whether, but not what, how, and when
disclosures occur. With HD as well, disclosures may
be affected by guilt, fear, shame, or discomfort. Yet
how individuals at risk for HD experience, view, and
approach these issues, and how these factors affect
disclosure decisions have been under-explored.
In contrast to many other disorders, HD invariably
affects other family members. Disclosures may also
have psychological implications that can in turn
shape subsequent health decisions. With breast
cancer, obtaining test results can profoundly affect
family members [Dudok DeWit et al., 1994], and
psychological distress may decrease with disclosure
to sisters, while increasing with disclosure to young
children [Lerman et al., 1998].
According to the Health Belief Model, an indivi-
dual’s health behavior is shaped by perceived
susceptibility, disease severity, and costs and bene-
fits of the behavior [Rosenstock et al., 1988]. Such a
model may apply to decisions about HD disclosures
and testing decisions, but has not been examined in
these contexts. Individuals often learn that they are at
risk for HD when they have been informed by family
members who are themselves at risk, mutation-
positive, or symptomatic. Thus, whether, when,
how, and to whom an individual discloses HD
information within a family may shape whether,
when, and how these members make decisions
about whether to pursue testing or have children.
How information is disclosed can also affect whether
and how one in turn eventually discloses it to others.
Recent policy changes may also mold these issues.
The Health Insurance Portability and Accountability
Act (HIPAA) protects health information generally.
Many states have enacted genetic privacy laws, but
these differ, and no federal genetic privacy law
currently exists [NCSL, 2006]. State laws remain
untested in courts, and debates exist about the merits
of ‘‘genetic exceptionalism’’—treating genetic and
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other medical information as distinct [Everett, 2004].
Nevertheless, physicians may feel important ethical
duties to disclose genetic test results to patients’
family members, if such information can prevent
harm, and would not otherwise be disclosed [Deftos,
1998].
Critical aspects of meaning and stigma may shape
HD disclosure decisions. Individuals ‘‘at risk’’ for
breast cancer experience this state subjectively as
‘‘somewhere between health and illness,’’ ‘‘a condi-
tion of non-health’’ [Gifford, 1986]. Goffman [1963]
has described how individuals with stigmatized
conditions struggle and seek to ‘‘manage’’ such
information, and ‘‘pass,’’ though such management
can be hard. But with HD, individuals manage
information for others, too, that is about these
others. Parsons has also described the ‘‘sick role’’ as
entailing rights and responsibilities, exemptions
from certain duties, and obligations to get well
[Parsons, 1951]. Individuals at-risk for HD must
choose, through disclosure decisions, whether to
put others and themselves into the role of being seen
as ‘‘at risk,’’ and what that means. On theoretical
grounds, too, Geertz [1973] has advocated studying
aspects of individuals’ lives and social situations not
by imposing theoretical structures, but from trying to
understand individuals’ own experiences, drawing
on their own words and perspectives to obtain a
‘‘thick description’’.
These issues are increasingly important, as on-line
websites are helping individuals to connect distant
relatives and construct genealogies (e.g., www.
ancestry.com), leading to disclosures of previously
unknown risks of HD and other genetic disorders.
Such on-line services can potentially facilitate
matches for tissue donations, but can lead to
awareness of hitherto unexpected genetic risks that
may not be optimally disclosed. Internet sites also
offer testing for other genetic disorders (though
not HD). In short, many critical questions remain
concerning how individuals who have or are at risk
for HD make these complex disclosure decisions,
and what factors are involved.
MATERIALS AND METHODS
To understand most fully the range of factors that
may be involved, we used qualitative methods and,
as summarized in Table I, interviewed in-depth 21
individuals—eight mutation-positive for HD, four
mutation-negative, and nine not tested—for 2 hr
each.
Potential participants were approached by staff at
an HD clinic. Attempts were made to ask all people
who underwent pre-symptomatic testing and a
range of others if they would participate. With each
participant, the principal investigator (PI) of this
project conducted a 2 hr in-depth semi-structured
interview concerning experiences of being at risk for
HD and undergoing the process of testing, and/or
learning one’s genetic status. Interviews were con-
ducted at participants’ offices or homes or in the

















1 F W Sx NT HS Housewife M 3 n/a 1
2 M B Sx NT 4 years college Professional M 0 n/a 2
3 M W Asx NT 4 years college Professional S 0 n/a n/a
4 M W Asx þ Some graduate Professional S 0 2 n/a
5 M W Asx þ <4 years college Professional S 0 2 n/a
6 M W Sx þ Some graduate Unemployed S 0
7 F W Asx þ 4 years college Professional M 2 1 n/a
8 F W Asx NT HS Blue collar M 3 n/a n/a
9 F W Asx NT <4 years college White collar M 1 <1 n/a
10 F B Asx NT HS Unemployed S 0 n/a n/a
11 M W Asx  Some graduate Professional M 0 (1 child
post-testing)
1 n/a
12 F W Asx  Some graduate Professional M 1 1 n/a
13 M W Asx  <HS Professional M 2 3 n/a
14 M W Asx þ 4 years college Blue collar M 3 1 n/a
15 M W Sx þ Some graduate Student M 0 6 1
16 F W Asx NT 4 years college Professional D 0 n/a n/a
17 M L Asx NT 4 years college Unemployed S 0 n/a n/a
18 M W Sx þ 4 years college Unemployed S 0 <1 <1
19 F W Sx NT 4 years college Blue collar S 0 n/a 5
20 M W Sx þ Some graduate Unemployed,
former professional
M 1 2 2
21 F W Asx  Some graduate Professional S 0 6 n/a
Race: B, black; W, white; L, latino/a. Symptom status: Asx, asymptomatic; Sx, symptomatic. Test status: NT, not tested;þ, positive test result;, negative test result. Level
of education: HS, high school. Some graduate includes those who did and did not complete degrees. Marital status: M, married; S, single; D, divorced.
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PI’s office—whichever was more convenient for
participants. The Columbia University Department
of Psychiatry Institutional Review Board approved
the study. Relevant sections of the interview guide
are attached (See Table II), through which we sought
to obtain detailed descriptions of the above issues
[Geertz, 1973]. Transcriptions and analyses of inter-
views occurred during the period in which the
interviews were being conducted. Interviews were
conducted until major and minor themes became
clear.
Interviews were analyzed, informed by grounded
theory [Strauss and Corbin, 1990]. Grounded theory
involves both deductive and inductive thinking,
building inductively from the data to an under-
standing of themes and patterns within the data, and
deductively, drawing on frameworks from prior
research and theories. Once the full set of interviews
was conducted, analyses were conducted in two
phases, primarily by the PI together with a research
assistant (RA) who had social science training. At
several points during the coding process, we also
received input from an additional, senior expert in
qualitative research.
The PI and the RA independently examined a
subset of interviews to assess factors that shaped
participants’ experiences, identifying categories of
recurrent themes and issues that were subsequently
given codes. The coders assessed similarities and
differences between participants, examining cate-
gories that emerged, ranges of variation within
categories, and variables that may be involved. The
coders developed a coding manual and examined
areas of disagreement until reaching consensus
between them. New themes that did not fit into the
original coding framework were discussed, and
modifications were made in the manual when
deemed appropriate. In phase 2 of the analysis, we
refined and merged subdivided thematic categories
into secondary or sub-codes, when suggested by
associations, or overlap in the data. Codes and sub-
codes were then used in analysis of all of the
interviews. To ensure coding reliability, two coders
analyzed all interviews. Again, we examined areas of
disagreement until consensus was reached. Major
codes included for example telling children and
telling parents. Sub-codes (or sub-themes) included
specific reasons to tell or not (e.g., telling to receive
support, or not telling in order to avoid burdening
parents). We conducted thematic content analyses,
and to ensure rigor and trustworthiness of the data,
we used two coders and an outside consultant, and
triangulated coding categories and methods, refer-
ring to the published literature, as described above.
Moreover, our findings appear to have a certain
face validity. The New York State Psychiatric Institute
IRB approved this study and all participants gave
informed consent.
RESULTS
Critical themes arose in families, with each
disclosure decision involving key questions of what,
how, when, why, and whom to tell. Overall, these
themes suggest a framework or model as illustrated
in Figure 1. In general, what, how, why, and when
disclosure occurred was shaped by who was told.
Reasons to disclose or not were shapedby the type of
relationship (i.e., telling a parent vs. siblings vs. an
older or younger child). Below, these domains are
organized and presented separately and sequentially
to provide a sense of each. Yet clearly, these
categories are closely inter-related. Following dis-
closure, questions emerged concerning whether and
to what degree to encourage offspring and other
family members to pursue testing themselves.
What to Tell
Individuals struggled with questions of what to tell,
and disclosed a range of information—for example,
that they suspected that they might have either
symptoms or the mutation, have initiated genetic
counseling, or have gotten test results.
At one extreme, a few disclosed nothing to certain
family members (e.g., ‘‘I’ve told nobody except
my husband—not my siblings’’ [7:F/Asx/þ]) But
such non-disclosers tended to be asymptomatic.
Other individuals made more fine-grained disclosure
decisions.
They had to decide, for example, whether to tell
that they merely suspected symptoms (e.g., ‘‘if I have
a little sort of twitch in my hand: is that the sort of
TABLE II. Sample Questions From Semi-Structured Interview Guide
When did you learn that you were at risk of HD and what was your reaction to it at that time?
Have you had genetic testing done? If so, what was the result and how did you respond?
Have you ever felt stigma or discrimination because of HD?
Have you been concerned about threats to privacy? How so?
Whom have you told or not told about your risk for HD?
Have you told family members (spouse/significant other; sisters; brothers; parents; children; other extended family members; in-laws)? Health
care professionals (primary physician or other physician in different contexts) or others?
In each case, what, when, and why did you disclose?
How have you made these decisions?
Have you ever disclosed to someone who then told others? Has your health information ever ‘‘leaked out’’ or led to discrimination, and, if so,
how?
Do you have any other thoughts about these issues?
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thing that I want to trouble my mother and my sister’s
family about? Probably not, unless I was fairly
certain.’’ [15:M/Sx/þ]). Partial information could
frighten others, perhaps unnecessarily.
Codedor onlypartial informationmaybedivulged.
Individuals could disclose that they had initiated the
counseling process, and/or that they had undergone
the actual test.
I didn’t tell anyone in my family except my
little sister that I was doing this. She knew I
initiated the testing, but she had no idea how
far along in the process I was. . .They thought I
was still in the counseling session, though I’d
had the blood drawn. . .The night I found out
I was gene negative, I. . .told them. . .I didn’t
want anyone. . .watching for signs of how I
was doing. I had gotten good at obfuscating
things, which I was never good at before:
‘‘yeah, things are still in process.’’ [12:F/Asx/-]
Though asymptomatic, she still assumed she might
have the mutation, and hence withheld information.
Others revealed only that HD was a possibility—
even if it had in fact been diagnosed—that particular
symptoms had developed, but not mentioning a
diagnosis per se. Some said ‘‘ataxia’’ that was not
specific, for example, rather than use the label ‘‘HD.’’
HD was purported to be multiple sclerosis, alcohol-
ism, or ‘‘nerves.’’
Within families, overt deceit can be encouraged
and defended. Older family members may dissemble
to offspring who were now in their 40s, and still did
not know.
My aunt and uncle lied to their offspring—
my cousins—and said my mother has MS. My
cousins have to know something’s wrong with
her. My aunt was adamant: ‘‘do not tell!’’ I have
no reason to tell her children. We’re not that
close. It’s her business. [8:F/Asx/NT]
This interviewee felt justified in her reticence,
since her relationship with her cousins was not
close enough, she felt, to obligate divulgence.
Yet silence can in fact generate lies, since family
members may ask questions.
My daughter said to me, ‘‘Where are you
going?’’ I said, ‘‘The hospital.’’ They know
I come here. They think it’s for cancer: ‘‘I’m
going on a test study for people who are
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FIG. 1. Model of factors weighed in disclosure decisions.
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Untested, she did not want to disclose even her risk
to her daughter. As she suggested, too, lies vary in
size anddegree, with differentmoral implications—a
‘‘little’’ vs. ‘‘a lot’’, ‘‘white’’ vs. other. ‘‘White’’ suggests
innocence and innocuousness of a lie—ostensibly
making it less ethically problematic. In her mind, this
concealment was not as egregious as some others—
for example, denying the presence of a known
disease.
Though at first, many tried to hide evidence of the
disease, at a certain point, visible symptoms preclude
concealment. (‘‘I try and minimize my movements so
people won’t actually notice. So I can try and walk
like normal people. . .’’ [2:M/Sx/NT]) The view of
oneself as ‘‘normal’’ suggests how HD is seen as
‘‘abnormal’’ and is thus stigmatized, motivating
caution in disclosures.
How to Tell
How to disclose also proved difficult. Individuals
had to gauge how to ‘‘prepare the ground’’ in
advance, over time, to minimize responses of
shock—whether the information is that one is at-risk
for HD, or has been found to have the mutation.
What I’ve really learned is: it’s how you
tell. . .If I find out horrifying news, and run
home, and just blurt it out, and don’t prepare
the ground—I’ve attacked people with it. The
way people talk to each other about this stuff
can really make a difference! [12:F/Asx/-]
Disclosure can thus occur as a process over time,
and be gradual or abrupt.
Disclosures also varied in the degree to which they
entail discussion of relevant additional information.
Discussion can be threatening and ultimately over-
whelming, and hence eschewed. Siblings, for exam-
ple, also at risk,maynotwant, or be able to, discuss it.
There really isn’t much left to say, other than
I got tested, and was positive. . .there wasn’t a
lot of back and forth about them getting tested
or not. [4:M/Asx/þ]
His perception that there ‘‘isn’t much left to say’’
suggested, too, the possibility of mutual avoidance
of further discussion (i.e., between tellers and
listeners).
In part, families vary a priori in styles and norms of
communications (e.g., ‘‘My family does not commu-
nicate well about their emotions. They really just
keep things completely to themselves.We’re not . . . a
very talkative family.’’ [4:M/Asx/þ]).
Since explicit conversationmay be too threatening,
indirect or implicit rather than explicit communica-
tion, or nervous humor can prevail.
My sister and I never spoke about it, or about
her getting it. . .We probably will have that
conversation one day. But I guess we speak
about it in conversation without speaking
about it. She might even say, ‘You know, we
can get that disease one day.’ I’ll say, ‘‘I know.’’
But we don’t get into details. We’ll just talk
about what our brother’s doing. . .and we
laugh about some of the crazy things he
does. . .Not, ‘What would you do if you
got it,’ or ‘Are you going to get tested?’
[3:M/Asx/NT]
They could, but do not, discuss a wide range
of ‘‘details’’. He felt they should have more of a
conversation, but they did not do so, since the
conversation was personally too threatening. Given
this tension, he saw them as delaying the conversa-
tion, rather thanpermanently prohibiting it. Still, they
communicate indirectly (e.g., about mutual anxiety
or unease).
As above, such reticence can build on long-
standing histories of silence—over multiple genera-
tions—arising in part from not only general family
communication styles, but expressed minimization
or denial of this particular problem.
We didn’t have those conversations growing
up. My father never talked about it. He’d
act like nothing was wrong, like my mother
was Ok. . .he never wanted to talk about it.
[14:M/Asx/þ]
This interviewee now had to make disclosure
decisions, having had denial and deceit as his only
models. How one’s parents discuss HD can shape
howone later talks about it to one’s ownchildren and
siblings.
Alternatively, disclosure may transpire immedi-
ately and unhesitatingly because it is fully expected
within the culture and implicit norms of a family.
Familymembersmay simply expect to be told. A Latin
American man said,
We like telling people, especially in my
country, because one day [my father] will be
dead, and why was he dead? Why didn’t they
tell us? The whole family knows. They are
totally aware. They have to be. We have to be
totally straight up honest. . .or else they will
never forgive us. [17:M/Asx/NT]
One could later be blamed for non-disclosure.
Of note, he was asymptomatic and untested—states
that may be less difficult to disclose than having the
mutation.
Particular questions arise concerning what and
how to tell children, since they often have less
capacity to understand or cope. Such disclosures and
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discussions can varywidely in their components, and
be indirect or even non-verbal.
My mother said, ‘The neurologist said: at
breakfast one morning, put this booklet about
HD on the table. If no one asks about it, don’t
worry about it.’ [5:M/Asx/þ]
Thus, the existence of the disease can be broached,
but not the fact that family members may have it.
Especially with children, partial and incomplete
information may also be given piecemeal over
several years, generating misunderstandings. (‘‘The
information just leaked out in bits and pieces over a
number of years. . .You hear people saying things,
you get the wrong idea.’’ [5:M/Asx/þ]). Incomplete
information can thus foster misunderstandings
about what was not being said. An informed
individual may tell other family members, constitut-
ing ‘‘secondary disclosure,’’ though the original
discloser may object, creating tensions. (‘‘My mother
told me she was going to tell my older brother, but
not my younger brother and sister until they were
older’’ [7:F/Asx/þ]). Hence, an individual’s diag-
nosis may be disclosed not by that individual,
but by another, with or without the diagnosed
individual’s permission.
Yet given gradations in children’s cognitive and
emotional maturity, input from HCWs can perhaps
particularly help parents with disclosures.
My mother should not have been the one
to tell us, but a therapist, a social worker.
Somebody should have sat down with
my parents in the room. . .We found out in
a bad way. We never discussed it together.
[5:M/Asx/þ]
Disclosures can thus vary in quality, as relatively
‘‘bad’’ or ‘‘good’’ according to several parameters.
Why Tell
Issues arose concerningwhy tell or not tell, shaped
by who was being told. Generally, similarities and
differences arose between types of relationships—
that is, parents telling offspring, offspring telling
parents, and siblings telling each other. Separate,
though related reasons to tell or not tell emergedwith
siblings, parents, children, and extended family
(cousins, aunts, and uncles). For many, the very
meaning of genetic disease is that other family
members are risk, yet the issues involved in
disclosure differed somewhat by categories of
relationships. Still, certain questions and concerns
were shared.
Once symptoms appear, disclosure may become
both unavoidable and essential for coping optimally
with the illness. As one symptomatic but untested
woman said, ‘‘I don’t really think I can live a normal
life if I don’t have a few people close to me who
know.’’ [19:F/Sx/NT] She felt she had to tell at least
some people in order to gain instrumental support
for the stresses posed by the illness.
Family members were thought to have the right to
know if they were at risk. Specifically, many
individuals disclosed because of perceived respon-
sibility to foster the health of family members,
enabling these others to pursue appropriate medical
evaluation and family planning, if desired. Disclo-
sure thus also occurred to avoid potential further
transmission of the mutation. Adult offspring, too,
felt that their parents, even if not wanting to find out
more about HD and deal with it themselves, had an
ethical duty to tell them at some point.
Yet tensions emerged because the information
could burden the recipient. These feelings often
stemmed from other, prior experiences and interac-
tions, and desires to avoid troubling elderly parents
already overwhelmed by the effects of HD. Indivi-
duals often feared that parents, if told, could feel
guilty about having transmitted the disease. Though
such feelings may not be rational, even a parent not
at-risk may experience such guilt about not having
stopped the potential spread of a spouse’s mutation
to children. As one man, whose mother had died of
HD, said, ‘‘Itwas hard to tell my father, not because of
privacy, but because he felt guilty. . .that he might
have passed it on. . .After my parents had my
youngest sister, the doctors told them they shouldn’t
have any more children’’ [6:M/Sx/þ].
Parents may justify non-disclosure to children
based on desires to avoid burdening these offspring.
These decisions are difficult, pitting secrecy in the
name of protection against risks of further spread of
the gene. One woman reported that her parents said,
‘‘We were just protecting you. We didn’t
want you to deal with it. We had 30 good years
before this hit us. Why can’t our kids have a
childhood? Let’s let them enjoy their child-
hood, and not worry about their health.’’
[8:F/Asx/NT]
Here, too, issues of when to tell emerge.
Some hesitated to disclose information, since to
do so can also be painful, and compromise one’s
confidentiality. To bestow on others trust and
knowledge allots them power that they could then
use against one. HD risk led many to be cautious in
disclosing information more generally.
If you tell someone how you feel, you give
them a gift. You’re trusting them to be able to
respond to your feelings in a helpful way. It’s
been very useful to me to hide some things.
[12:F/Asx/-]
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This knowledge can constitute a ‘‘gift’’ because it
affirms trust—closeness and a particular relation-
ship—and gives others a certain power, since they
could spread the knowledge. Yet the disclosure can
also strengthen the relationship—demonstrating
such trust. People may appreciate being told, since
they can also make constructive use of the informa-
tion (e.g., being able to offer support).
The fact that HD causes psychiatric symptoms also
impeded disclosure. Individuals made assessments,
too—correctly or not—that family members,
because of age and psychological fragility (due in
part to possible symptoms), could not handle the
information. Differences may be perceived in the
emotional vulnerability versus resilience of siblings.
Individuals may vary psychologically in their coping
styles—for example, taking more emotional versus
rational approaches. (‘‘When bad news comes, my
mother, sister, and brother. . .immediately. . .think
of the worst. . .I am definitely more organized and
together’’ [7:F/Asx/þ]). Psychiatric symptoms are
also stigmatized, adding to HD being a ‘‘big secret in
the family.’’
No one talks about it, or says they’re at risk.
My sister-in-law and I talk 10 times a day. She
said, ‘‘It’s not cancer—an acceptable disease—
or Parkinson’s. Because it affects you mentally’’
. . .my mother. . .embarrasses us, saying dopey
things to people. . .People always look at her
as if she’s drunk. [8:F/Asx/NT]
Even without symptoms, being at-risk can be too
difficult to discuss, in part because psychiatric
symptoms can cause discrimination and generate
additional fears, representing loss of control, and not
generally being fully treatable.
Yet psychiatric symptoms can themselves impede
responses to disclosure either directly (through
symptoms) or indirectly (through stress that results).
HD may adversely affect parents’, spouses’, siblings’,
or children’s abilities to interact with others. Family
members, particularly parents, may be insensitive or
not fully supportive. (‘‘I wasn’t going to tell my
mother, because I didn’t feel I would get any support
from her. She. . . is generally not good at under-
standing.’’ [5:M/Asx/þ])HDcan thus pose obstacles
to good parenting that compound these difficulties.
Particularly among siblings, strained and estranged
relationships can impede disclosure. Though some
siblings immediately informed each other, since
if one had the gene, others were also at risk,
obstacles—related to the nature of the relation-
ship—could impede or prevent these divulgences.
Given the anxieties involved, siblings may simply not
want to know (e.g., ‘‘I asked my brother. . . ‘‘Would
you want to know if I’m positive or not?’’ He said no.’’
[7:F/Asx/þ]). An individual could often approach
each sibling differently, based partly on perceptions
of that sibling’s resilience and possible symptoms, or
responses to a prior question of whether the sibling
would want to know. Family members were felt to
have a right not to know if they wished. Avoidance
of disclosure can also verge on denial that can
potentially hamper treatment.
Even though my older brother lived like
he had the disease anyway, he didn’t really
want to talk or know about it. We tried to
get my twin to see a therapist. He went once.
[5:M/Asx/þ]
Even if both tacitly know their mutual risk, siblings
may avoid discussing it prior to disclosure due to the
threat of disease. (‘‘My brother just skirted around the
issue. I asked direct questions and wouldn’t get any
answers back.’’ [21:F/Asx/-])
When to Tell
Decisions of when to disclose were shaped by two
sets of time frames—that of the life cycle of the family
memberwho is told, and that of themedical courseof
the affected members. Within families, concerns
about disclosure issues tended to increase at critical
junctures in the life cycle of at-risk individuals—at
points of marriage, engagement, or having children.
When and how disclosures occur can be closely
related. Though careful plans may be made con-
cerning disclosure, advanced decisions can be hard
to carry out, and the information can instead simply
leak or get blurted out (‘‘I didn’t tell my mother.
Then we ended up having an argument, and I
told her, which is exactly what I didn’t want to do.’’
[5:M/Asx/þ]). Without symptoms, the revelation
that one carried the mutation could shock others
because the disease was not yet visible.
Decisions of what and when to tell also shaped
each other. Some wondered, for example, if they
should tell when suspecting symptoms, versus wait-
ing until initiating testing, or obtaining results.
Conundrums of when to tell arose particularly with
children. Dilemmas of at what age and juncture to
disclose a parent’s disease are important since when
a parent discloses to his or her offspring, the latter is
thereby learning of his or her risk status—usually for
the first time. Young children may feel overwhelmed
by too much information about a parent’s disease,
but utter silence can cause harm as well.
A few learned about their risk as relatively young
children, but varied in how they later viewed their
parents’ decision to disclose at that point. Certain
information about HD can be helpful, even if
frightening. As one man said,
I was ten when I first found out. I was very
stressed out about it, very depressed, unable to
sleep for a while. It was really tough, hearing
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that I was at risk for the disease. My mother
told me that she had children because there
might be a cure for the disease eventually.
I was actually okay with that. . .But for a long
time it was very tough—the fact that I might
get a disease like my mother. . .Me and my
sister were able to understand at ten. . .My
mother first showed symptoms when we were
8 or 9. My aunt also had HD, and was 15 years
older than my mother, so they were able to tell
us that ‘it’s probably going to be like what your
aunt has.’ [18:M/Sx/þ]
He thinks it was appropriate that he was given
information when he was.
Looking back on it, it was very right. . .She
just told me about the disease so that I could
understand. My pediatrician did the same. He
could have told me all these facts about the
disease. He told us in a way we could
understand at ten: that there is a fifty/fifty
chance, so we were able to understand about
our own risk, and what to expect with our
mother’s progression. . . [18:M/Sx/þ]
Here again, who is told shapes what is told: young
children can be given age-appropriate information.
Ironically, the fact that the disease is genetic, and thus
visible in other kin, may make it less abstract and
more understandable, even if still frightening.
Still, others felt that they were told too early—that
they were too young for the information they were
given. A critical distinction emerged, for example,
between knowing about the disease in general (and
that it affected a parent) versus knowing that one was
at risk oneself.
For a 15-year-old girl, that’s a lot to put on her
shoulders. But my dad thought I was up to the
task. He has always confided in me as a friend
rather than daughter—things like money
worries. I don’t think he should have done that
at an early age, because I used to worry for him.
It made me older than I should have been. . .I
grew up very young. [21:F/Asx/-]
She now felt that 15-year-old should not be told.
Yet the age at which one is ‘‘old enough’’ may not be
clear.
I don’t know how one should decide when
one is old enough. That’s very personal,
hard. Everyone’s individual. Maybe it’s when
someone’s in a stable, happy point in their
life. . .someone getting ill has to know. That’s
the cut off point: when they’re ill. [21:F/Asx/-]
Criteria thus arose of being stable, ‘‘happy,’’ and
cognitively and emotionally mature.
Alternatively, some felt that they were told too
late. Disclosure may not occur until an offspring’s
marriage—transpiring only then so that prospective
spouses might know before they marry and consider
children.
Growing up, I was aware that MS was in the
family, but never really thought about it. Then,
I got engaged to my husband. My mother
said—like she had been keeping a family
secret—that it wasn’t actually MS, but HD.
She wanted to tell me before we got married,
because she didn’t want my husband to
marry into the family when this was there.’’
[7:F/Asx/þ]
This woman was angry at her mother’s both non-
disclosure and view of the disease as shameful.
Similarly, another woman reported that her sister,
with 22 and 20 years old sons, said,
‘‘When I know that my oldest is going to get
married, I’ll tell him.’’ But isn’t that too late—
waiting until he’s engaged. . .? Now that he’s
met the woman of his dreams, he’s going to hit
her with this? That’s wrong. [8:F/Asx/NT]
Adult children at risk might not be told by a parent,
and they may then have children themselves, not
knowing of the risk. In keeping the family’s
HD secret from children, and then disclosing it ‘‘too
late,’’ such delay and dissembling may incur later
resentment.
Now we find out, when we’re 24, that they’ve
been lying to us our whole lives. They knew
about this, and didn’t do anything. I’ve been
dating my husband since I was 16. So, if she
wanted to make sure we didn’t get serious, she
should have told me way back then, not after
we’ve been dating seven years. [7:F/Asx/þ]
Several factors may account for such delays. Some
thought that over recent years, attitudes towards HD
disclosure have changed. The older generation may
have kept HD more of a secret, as it was less
understoodandperhaps as a resultmore stigmatized.
The timing of disclosure may be based, too, on
parents’ perceptions of offsprings’ maturity. Hence,
not all offspring may be told simultaneously.
Disclosures to children may come in waves, since
offspring may be of different ages—often spread out
over a decade or more. Hence, within a family, some
siblings may know while others don’t, forcing those
who know to maintain secrecy.
Telling Extended Family Members
Separate though related quandaries emerged of
whether and when to contact extended family
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members, including ‘‘long-lost relatives’’ who may
unknowingly be at risk. Such contact can constitute
the only notification long-lost kin receive that they
are at-risk. Yet with extended relatives, rules were
unclear, since patterns of relationships are more fluid
and less socially prescribed. Someattempted to reach
out to somewhat distant relatives, yet decisions of
what and how to communicate could be hard, and
the ideal tone of such missives difficult to achieve.
Such letters can be troubling not only to send but to
receive, in part because they are utterly unexpected.
(‘‘It came out of nowhere, a surprise. I wasn’t
expecting anything.’’ [13:M/Asx/-]) Many tested
individuals lacked detailed knowledge about
extended family members (‘‘My mother had 9
siblings. My grandmother had 10, of which 9 had it.
I have second cousins in different places. I don’t keep
in touch with them. I don’t know of any diagnosed.
[6:M/Sx/þ]). He thus felt justified in not contacting
them. Distance can perpetuate further distance, and
conversely, closeness can foster added closeness.
Relatives may not be contacted because they’re
‘‘long-lost,’’ or, even after being contacted, further or
reciprocal communication may not occur.
I don’t have a deep sense of connection to
them. It would be like contacting a near
stranger. We’re connected in having a family
history, but I don’t have an emotional connec-
tion to them. [13:M/Asx/-]
Individuals may be close biologically, but not
socially. Questions surfaced, too, of how to reply to
information from a distant family member. Distance
may be mutually perceived. (‘‘I might have
responded with ‘‘I’m sorry,’’ but it was minimal.’’
[13:M/Asx/-]) Other obstacles may block such
disclosures as well. As above, family members may
object to disclosures to particular relatives, and
explicitly tellmembersnot to inform certain relatives.
(‘‘My dad’s brother called my mother, but didn’t want
his kids to know. I was not to speak to them about
it. . .’’ [7:F/Asx/þ])
Given various obstacles, warnings to long-lost
relatives of their HD risk may get ignored—letters are
discarded or put away, all but forgotten.
The day I learned about HD in our family,
my father gave me a letter from my mother’s
first cousin in the South saying that someone
had HD, and was there anyone else in the
family showing signs? This letter had been
written years before. It had been in his drawer
3–4 years. My parents had ignored the letter,
and not gotten back to them, which I found
appalling. ‘‘How could you? Someone in our
family is reaching out for help!. . .you’re not
even contacting these people to say: yes, we
do have it in our family. You knew this was in
the family, and you just chose not to tell us!’’ I
called this cousin that day, got in touch with
the son and daughter, and became friends with
them. [8:F/Asx/NT]
Thus, disagreements can occur about not only
informing non-immediate family members, but
responding to the information once received. With
distant (vs. close) relatives, the social, and hence
ethical bonds were less, leading to less involvement
with, and knowledge of, these relatives’ reactions
and responses.
My cousins have thought about testing. . .
I don’t know if they’ve made much progress.
We had never really talked about their issue
until after I got my results. . .My cousin thought
I had the bigger burden to carry. I’m not going
to bother him with my own life. . .I had a 50–
50 chance, and they had a 25% chance. . .
[11:M/Asx/-]
Extended family members may simply not want
such communication. Relatives at risk may just refuse
to deal with it, and not respond when urged to do so.
‘‘I have a cousin. His mother died of it. My sister tried
to contact him 3–4 times, but he won’t return her
calls. He’s probably very scared.’’ [18:M/Sx/þ] In
part, not to bother contacting such relatives is easier,
but such communication can in fact prove helpful.
The type of relationship (e.g., immediate vs. distant
family; emotionally close vs. distant) can shape how
these factors are balanced as well. Importantly,
biological and psychological bonds shaped percep-
tions of these ethical bonds. Distance (vs. closeness)
in the relationship—that is, being extended family
members or estranged—reduced the sense of res-
ponsibility to aid one another’s health.
Testing Family Members
As seen on Table III, post-disclosure, difficult
questions arose, too, of whether to pressure family
members—adults or children—to be tested, and if
so, to what degree.
For several reasons, some sought to get family
members tested—often to gauge a third party’s risk.
Some wanted a parent tested, for example, so that
neither they nor their kids would have to undergo
testing themselves. (‘‘I said to my mom, ‘I want you to
be tested for us.’’’ [8:F/Asx/NT]) Her kids would
then not be at risk if her mother were negative. Yet
that desire required her to pressure her mother to
test. A parent may readily agree, given the trade-off,
or feel imposed on. Hence, individuals had to
balance their own rights and desires versus their
perceived obligations to other family members.
Disagreements occurred.
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Yet others deferred from pressuring family mem-
bers—particularly those who show symptoms—
from getting tested. One woman thought her brother
had early HD symptoms, but would not cope with
the result well. Thus, she did not want him tested.
I think my brother has it. That’s why I don’t
push him anymore to get the test. Huntington’s
people get a look in their eyes. . .even when
there’s no signs or symptoms—a glazy, spaced
out look. . . [21:F/Asx/-]
Others did not want very young or very old certain
family members tested, and actively deterred them.
Yet the reasons family members may seek to
dissuade each other from being tested may or may
not be seen as valid.
My grandmother tells my aunt and uncle
they might eventually die—which is true. But
she scares them off. My aunt is petrified [by
my grandmother] of this whole situation, to
where she doesn’t want to get a test done.
[10:F/Asx/NT]
Within the same family, individual receptivity to
the option of testing can vary dramatically, due in
part to personalities and perceived repercussions of
test results.
Everybody has such different opinions on it.
I’m the only one out of 5 in my family that will
be tested. The rest refuse, except my sister
who. . .feels she’s showing signs. [8:F/Asx/NT]
But this interviewee herself had not yet been
tested.
Strong feelings emerged about not only whether
family members should be tested, but when. Some
encouraged family members to get testing at
particular times—seeing benefits at particular junc-
tures. One man told his brother to test before their
father died of HD, in order to arrange for insurance.
You should get your insurance straightened
out soon. When he died, it got more difficult.
Then, if they ask you, ‘‘Are your parents alive?
What did they die of?’’ You have to lie, and
potentially they could invalidate your insur-
ance. [13:M/Asx/-]
Yet despite possible symptoms, some family
members refused to seek evaluation.
I said at to my sister-in-law, ‘‘Do you think
my brother could be showing any signs? He
has anxiety, depression.’’ She said, ‘‘He might
be, but he’ll never come in.’’ [8:F/Asx/NT]
Others’ Input Into Disclosure Decisions
As mentioned earlier, dilemmas arose of how to
negotiate disagreements about disclosure within a
family (e.g., of whether to tell cousins, if their parents
do not want them to know). Even spouses could
vehemently disagree about disclosures (‘‘I try not to
bring it up with my husband. It’s my only argument
with him.’’ [1:F/Sx/NT]). In disagreements about
disclosures, generally, closer relatives’ assessments
prevailed. More distant relatives deferred, since
less biological closeness was felt to lessen ethical
obligations.
HCWs have potential input in disclosure decisions,
yet their roles were rarely, if ever, mentioned. At
times, genetic counseling was seen as falling short
because it did not prepare individuals to deal with
disclosure issues. (‘‘I didn’t know who to tell, or what
to say. I wasn’t prepared for it.’’ [8:M/Asx/þ])
DISCUSSION
These data illustrate the complexities involved in
disclosures by individuals who have or are at risk for
HD to their family members. Tensions arose related
to ethical, social and psychological concerns. Impor-
tantly, these data revealed issues not examined
previously concerning what and how individuals
disclose, whether disclosures occurred to extended
family members, and whether family members were
tested post-disclosure. Issues concerning disclosure
to close more than to distant relatives have been
explored with other disorders (e.g., hereditary breast
and ovarian cancer [Hughes et al., 2002; Wagner-
Costalas et al., 2003]), but not heretofore with HD.
Some individuals, informed that they were at risk for
HD, pursued genetic testing, and were glad that they
had been told, enabling them to make informed
decisions about their lives. Yet in other instances, the
information was disclosed, but then essentially
ignored. Often, due to the potential stigma, only
partial or indirect information was provided. Dis-
closure decisions were based on several factors,
including perceptions of others’ ability to handle the
information, intra-familial norms of communication,
and one’s own comfort with the results. While
TABLE III. Issues Involved in Testing Family Members
Family members vary in their interest in testing
Individuals can encourage others to test
To know others’ risk
Individuals can choose not to push
Because of a family member’s vulnerability
Because of others’ rights
Individuals can dissuade others from testing
Individuals face decisions of when to discuss and/or encourage
testing:
For example, before parent dies but after getting insurance
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advanced plans for disclosure might be made and
carried out, emotional factors could make disclosure
decisions not always rational and predictable. At
times, the information got blurted out.
Importantly, while HCWs may encourage indivi-
duals at-risk for HD to disclose that fact to family
members who are also at risk, such disclosure may
also then entail divulgence of one’s own diagnosis. It
is very difficult to disclose that one is at-risk or has
initiated testing without also then divulging the test
result—which, if positive, constitutes one’s diagno-
sis. Disclosure may prompt questions or obligations
concerning the discloser’s own test results. Yet such
disclosure of diagnosis can be difficult, depending
on previous family communication style and knowl-
edge of the disease. This information can be
stigmatized, and change others’ perceptions of one,
even in one’s own family.
Other obstacles to disclosure—even of being at-
risk—may exist as well. These disclosure decisions
can be part of dynamic processes. Here, distance
and closeness can also each be self-perpetuating.
Between people, non-disclosure, too, can be
mutually reinforced—constituting a policy of ‘‘don’t
ask, don’t tell.’’ Even being asymptomatic, if un-
tested, is hard to disclose and can lead to lies.
Individuals who know they do not have the mutation
may face less difficulties, but not entirely if their
disclosure involves informing others that these
others are in fact at risk. Patterns of disclosure or
non-disclosure can also extend over more than one
generation, possibly becoming self-perpetuating.
Importantly, many of these individuals had strong
feelings and attitudes toward other family members’
both disclosure decisions and views of the disease.
Our findings both resembled, and differed from,
those of prior studies. Forrest et al. [2003] found that
in Northeast Scotland, the right time to tell children
wasusuallywhen theywerepotential parents, that is,
about to be married. In our sample, parents often
faced these issues earlier. Perhaps in part, in anurban
US setting, offspring may have children later, if at all,
as opposed to in Northeast Scotland. Thus, even
between Western countries, both similarities and
differences may arise. Systems of health insurance
vary between countries in ways that may affect
disclosure decisions. Yet such international differ-
ences have received little attention in studies of
psychosocial aspects of HD. We found, too, that the
timing of disclosure occurred not simply based
on ‘‘prevarication vs. pragmatism’’ as in this prior
research, but that information sometimes got
‘‘blurted out,’’ for example, in arguments. Forrest
et al. found as well that individuals felt that some
relatives didn’t ‘need’ to be told, while in our data,
interviewees felt that some relatives also did not
‘want’ to be told—because of perceptions that these
others were feeling too fragile due to symptoms or
risk of HD. These prior investigators found that
women often served as gatekeepers of genetic
knowledge more than did men. We did not find that
to be as much the case—perhaps in part since they
interviewed 50% more women than men, and
included breast cancer (which affects primarily
women) as well as HD, while we examined only
HD. Hamilton et al. [2005] found that participants
confronting hereditary breast and ovarian cancer,
but not HD, tried to affect family members’ own
testing decisions. In our data, these issues arose
among participants facing HD as well. Hamilton et al.
did not discuss disclosures to adult children. The pre-
sent data suggest, too, that one’s own specific status
(i.e., not tested, mutation carrier, or non-carrier; and
symptomatic or asymptomatic) may affect some
disclosure decisions. Past studies have not assessed
these factors, but future research should do so.
Similar to the rational choice Health Belief Model,
which addresses whether individuals decide to
engage in health behaviors [Rosenstock et al.,
1988], we found that individuals weighed pros and
cons of whether to disclose, but that complex issues
and factors also arose concerning decisions of what,
how, and to whom, to disclose. Factors were not
always rational (i.e., the information sometimes got
‘‘blurted out’’). These data illustrate, too, Goffman’s
theories of how individuals seek to ‘‘manage’’
stigmatized information about themselves. Yet here,
these desires can conflict with ethical notions of
responsibilities towards one’s kin; and of truth-
telling. Sissela Bok in Lying: Moral Choice in Public
and Private Life [Bok, 1999] held that people should
never lie. In contrast, David Nyberg in The Varnished
Truth [Nyberg, 1980], asked, ‘‘what’s so good about
telling the truth all the time?’’ and argued that telling
lies is an intrinsic and necessary part of human life.
Desires to conceal can clash with perceived needs to
tell the truth. These conflicts then often get decided
based on various other factors (e.g., degrees of
closeness, and age of family members).
Future research with larger cohorts can assess
these issues, and the roles of various factors (e.g.,
family background vs. innate psychological traits)
further quantitatively. Future studies can assess, too,
the effects of when and how one is informed on how
one subsequently decides whether, when and how
to approach dilemmas concerning testing, reproduc-
tive options [Klitzman et al., 2007a,b], and disclo-
sures to others. Relatives who were disclosed to in
ways that they felt were adequate and appropriate
may make more optimal decisions about whether to
pursue testing. Alternatively, those who are dis-
closed to in ways that they feel are inadequate or
inappropriate may delay addressing their HD risk
in their own lives. Future studies can explore such
hypotheses, and assess views and ranges of defini-
tions of adequate versus inadequate and appropriate
versus inappropriate disclosures (e.g., in terms of
timing, quantity and quality of information, suppor-
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tiveness, and provision of sufficient information).
HCWs may recommend generally that a patient, if he
or she can handle it, inform relatives that he or she
will be receiving test results, and that these relatives
should ask the patient if they want to know the
results. This procedure allows these relatives to
choose if and when to receive such information. Yet
how patients and their relatives respond to such
suggestions, and why, remain uninvestigated.
Our data highlight the need, too, for future
research to be as sensitive as possible to differences
between varying genetic disorders due to particular
features of each disease (i.e., penetrance, treatability,
means of prevention, and presence of psychiatric
symptoms). Disclosures concerning HD may prove
more difficult than for many other disorders because
of not only being autosomal dominant and highly
penetrant, but also causing psychiatric symptoms
that can lead to stigma and discrimination. Issues of
disclosure to distant relatives take on more impor-
tance than with other diseases that pose less, if any,
medical risk to extended family members. Given its
penetrance, having an HD mutation may have more
powerful implications for extended family members
than certain other genetic diseases that are recessive
and less penetrant.
In these data, the questions of number of repeats
and indeterminate ranges did not come up as major
issues. Rather, most individuals who tested positive
took the positive result in and of itself as the signi-
ficant fact, and assumed that they were ‘‘mutation-
positive’’, in part because it appeared easier to live
with this certainty, even if it might ultimately prove
incorrect, than with the alternative of high ambiguity
and uncertainty. We will be exploring these issues
further in future analyses and research.
These participants discussed insurance concerns,
but generally not in the context of disclosures to
family members. When telling siblings or offspring,
these participants were generally more concerned
about the implications of the information for their
own health and well-being and that of these family
members and the latter’s offspring. The fact that these
family members may encounter difficulty getting
insurance appeared to be secondary to the potential
life and death issues these family members now
faced. Fears of discrimination, including potential
threats to insurance, shaped disclosure decisions in
social settings outside of families—for example, with
coworkers, bosses, friends, dates, and HCWs—in
ways that we are currently exploring further.
These data have important implications for genetic
counselors (GCs) and other HCWs. Interviewees said
HCWs rarely, if ever, discussed with them these
issues of disclosure, especially concerning extended
family members. Individuals at risk for HD thus
wrestle with these complex and nuanced issues
without professional guidance. Yet GCs and HCWs
can potentially be very beneficial in helping at-risk
individuals to consider these issues in advance.
Problems arose, for example, concerning secondary
disclosure: one family member who was told then
wanting to disclose that information to a third
member. A HCW can help at-risk individuals anti-
cipate these possibilities before they disclose to
family members. Individuals can potentially state to
these members that the information can or cannot
be shared with others. Such a request may not be
honored, but could at least be articulated. Questions
appeared as to not only whether these issues should
be addressed in genetic counseling sessions, but
how. Counselors may ask if disclosure occurred,
but what communication exactly transpired is
important—what the client disclosed or anticipates
disclosing (i.e., partial vs. complete information).
Counselors should also address obstacles to com-
municating information to extended relatives who
might benefit from the knowledge. Individuals may
feel reluctant to communicate to extended or
estranged family members in part because of inertia,
due to not having been in contact. But such
information may indeed be welcome. These data
suggest that these issues are rarely adequately
addressed in pre-test counseling sessions, high-
lighting the need for HCWs to discuss these issues
more with individuals who are considering genetic
testing—that is, to begin to consider in advance
whether, what, how, and when they should disclose
results to familymembers.HCWsneed to realize, too,
the extent to which these decisions are multi-
faceted—involving choices not only concerning
whether to tell or not, but what, when, how and to
whom to disclose. Many of these individuals would
have appreciated more guidance about disclosure
decisions to immediate family members, too. At-risk
individuals would benefit from enhanced education
and guidance concerning these issues. At the same
time, a HCW may push a patient to disclose to others
the fact that these others are at risk for HD, but that
disclosure may entail difficult divulgence of the
individual’s own diagnosis, too. Further research can
explore whether, when, how, and how often HCWs
discuss these issues with individuals considering
undergoing testing.
Professional training needs to make HCWs more
aware of the difficulties of these issues, particularly
when familial relationships may be strained—in part
because of HD in the family, and the stresses that can
result. Family therapists have developed effective
meansof addressing family disagreements [Minuchin
et al., 1996; Minuchin and Nichols, 1998] that might
prove beneficial to clinicians involved with genetic
testing.
These data also described journeys that at-risk
individuals underwent before entering a GC’s office.
Theymaybeat risk, but not learnof that fact for years,
even as adults. Or they may receive the information
indirectly, incompletely, or belatedly. To understand
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thesepotential obstacles is vital to ensuring that those
whomight benefit fromgenetic counseling andother
medical services are made aware of their risk as
appropriately as possible.
This study has several potential limitations. The
sample size may be small compared to some other
quantitative research, but is sufficient for a qualitative
study of this kind, to elucidate important themes that
emerge. We are unable to test statistically relation-
ships between gender, ethnicity, socioeconomic
status, and testing, and symptom status. However,
overall, these data reveal several suggestive and
important themes that can be pursued further in
future research with larger samples. We interviewed
participants at one point in time only, but they
described their past as well as present history of HD-
related experiences. These individuals are involved
with a tertiary care center, yet provided key insights
into responses toward HD by parents, siblings, and
extended relatives elsewhere as well. We have a
relatively high percentage of those who actually
tested, because we sought specifically to sample this
category, along with others. Yet this sample thus
provides valuable insights into how individuals with
a range of risk statuses view and approach these
issues.
Given the ethical and psychological complexities
of these issues, the development and promulgation
of enhanced guidelines concerning these activities,
based in part on data such as these, may help both
HCWs and at-risk individuals.
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